about
Optical detection and virotherapy of live metastatic tumor cells in body fluids with vaccinia strainsImaging characteristics, tissue distribution, and spread of a novel oncolytic vaccinia virus carrying the human sodium iodide symporterInsertion of the human sodium iodide symporter to facilitate deep tissue imaging does not alter oncolytic or replication capability of a novel vaccinia virusNovel oncolytic agent GLV-1h68 is effective against malignant pleural mesotheliomaAnti-VEGF single-chain antibody GLAF-1 encoded by oncolytic vaccinia virus significantly enhances antitumor therapyOncolytic virotherapy of canine and feline cancerInteraction and assembly of murine pre-replicative complex proteins in yeast and mouse cells.Drug-Encoded Biomarkers for Monitoring Biological TherapiesPreclinical evaluation of oncolytic vaccinia virus for therapy of canine soft tissue sarcomaEfficient colonization and therapy of human hepatocellular carcinoma (HCC) using the oncolytic vaccinia virus strain GLV-1h68Magnetic resonance imaging of tumors colonized with bacterial ferritin-expressing Escherichia coliCloning and functional study of porcine parotid hormone, a novel proline-rich protein.Prodrug converting enzyme gene delivery by L. monocytogenes.Functional hyper-IL-6 from vaccinia virus-colonized tumors triggers platelet formation and helps to alleviate toxicity of mitomycin C enhanced virus therapySystemic treatment of xenografts with vaccinia virus GLV-1h68 reveals the immunologic facet of oncolytic therapy.Correlates between host and viral transcriptional program associated with different oncolytic vaccinia virus isolates.Characterization of metastasis formation and virotherapy in the human C33A cervical cancer model.Regression of human prostate tumors and metastases in nude mice following treatment with the recombinant oncolytic vaccinia virus GLV-1h68.Viral-mediated oncolysis is the most critical factor in the late-phase of the tumor regression process upon vaccinia virus infection.Imaging a Genetically Engineered Oncolytic Vaccinia Virus (GLV-1h99) Using a Human Norepinephrine Transporter Reporter Gene.Combination treatment with oncolytic Vaccinia virus and cyclophosphamide results in synergistic antitumor effects in human lung adenocarcinoma bearing miceSignificant Growth Inhibition of Canine Mammary Carcinoma Xenografts following Treatment with Oncolytic Vaccinia Virus GLV-1h68.Evaluation of a new recombinant oncolytic vaccinia virus strain GLV-5b451 for feline mammary carcinoma therapyAn oncolytic vaccinia virus expressing the human sodium iodine symporter prolongs survival and facilitates SPECT/CT imaging in an orthotopic model of malignant pleural mesothelioma.Permissivity of the NCI-60 cancer cell lines to oncolytic Vaccinia Virus GLV-1h68Imaging of light emission from the expression of luciferases in living cells and organisms: a review.Antigen profiling analysis of vaccinia virus injected canine tumors: oncolytic virus efficiency predicted by boolean models.Bacterial glucuronidase as general marker for oncolytic virotherapy or other biological therapiesInducible gene expression in tumors colonized by modified oncolytic vaccinia virus strainsVisualization of tumors and metastases in live animals with bacteria and vaccinia virus encoding light-emitting proteins.Characterization and evaluation of a new oncolytic vaccinia virus strain LIVP6.1.1 for canine cancer therapyVaccinia virus-mediated melanin production allows MR and optoacoustic deep tissue imaging and laser-induced thermotherapy of cancer.Combination of fractionated irradiation with anti-VEGF expressing vaccinia virus therapy enhances tumor control by simultaneous radiosensitization of tumor associated endothelium.Vaccinia virus-mediated intra-tumoral expression of matrix metalloproteinase 9 enhances oncolysis of PC-3 xenograft tumors.PEG-pHPMAm-based polymeric micelles loaded with doxorubicin-prodrugs in combination antitumor therapy with oncolytic vaccinia viruses.Oncolytic immunotherapy using recombinant vaccinia virus GLV-1h68 kills sorafenib-resistant hepatocellular carcinoma efficiently.Preferential colonization of metastases by oncolytic vaccinia virus strain GLV-1h68 in a human PC-3 prostate cancer model in nude mice.Virotherapy of canine tumors with oncolytic vaccinia virus GLV-1h109 expressing an anti-VEGF single-chain antibody.Myristoylation negative msbB-mutants of probiotic E. coli Nissle 1917 retain tumor specific colonization properties but show less side effects in immunocompetent mice.Isolated limb perfusion with melphalan, tumour necrosis factor-alpha and oncolytic vaccinia virus improves tumour targeting and prolongs survival in a rat model of advanced extremity sarcoma.
P50
Q21132553-E7D9E97E-0D1E-4DFC-8334-66B9DC130745Q21134124-7FD882E7-914C-4ECE-B1C5-A9845542C577Q21245462-66BC5815-E9C0-494D-BF4F-4C816B26DB89Q24607747-24C0D5EA-4824-4A0D-9A8E-F9AC87AFC1EAQ24655930-B05A008A-9D2D-4757-95D3-41C1AA633D75Q27008306-8CF62707-1658-4E19-9582-703983E8409CQ27936124-E81A3799-B147-4445-A6D6-5CCC16B9939EQ28547768-C09A3ED8-A1A7-4526-BBC0-B34BFDB7A73FQ28729948-0EC8B562-61B1-495F-B199-9A6AF368AFD0Q28742749-3E1D37F1-7F93-4656-ACFF-4185F461E838Q28744347-944DA9F8-6FF8-491C-98EC-1755947746D9Q33213532-5477C775-5178-41D1-A33D-C1437F1E0B21Q33327560-3D8AEFD7-A524-48FF-BBCB-E63DAE99BEC0Q33399140-B92EC9F6-5197-40C2-B7FF-5F959D91C600Q33479314-16551790-9506-4EEF-897E-EC8A4677FEBBQ33587040-531F3C5C-0FD7-4538-B3B4-5D9A62C54BC9Q33700061-B30D40B6-3011-4580-AD8C-974EF827C6C9Q33772011-EA11C7A5-A5AB-4BA1-9714-0A02C4EF137BQ33820196-08E7E134-56E8-48CB-A040-454AB2B5411EQ33887850-E83E43E0-EE3B-49FB-AB79-10AC4117A162Q33927165-07A85955-7FE3-49DB-9F27-04BA70C37AF9Q33988096-7F65CB20-FDDA-48E8-82EC-4BD02EB2C228Q34005213-D8246C93-2637-4637-B431-852FE276EE30Q34011349-5B0CEB8D-6339-430E-ACB3-8A990C1533C4Q34051784-7E741F0E-4DD0-459D-B646-8C58803D1909Q34111739-5FEA2A47-BB6B-43CF-A5FB-48B245D084ACQ34142957-2FC16AE7-77C4-4AA3-9F82-57866D24584DQ34223150-A3896BB1-BE7C-49D8-BE52-2B674248E40FQ34262005-728EAC10-3FC3-4664-B3C2-E327ADF5BECAQ34301980-49FAAB15-C039-4667-B3D4-96381CF6D3ACQ34307934-2B49A375-4AE2-454A-927B-91CDEE9EAFD6Q34327349-610C41F8-46C4-465C-964A-26025804C1ACQ34348199-039602F1-E305-4828-BA8B-B0AAF512E181Q34392057-B6E781F7-1B90-4C28-8CFA-8A8C63574062Q34403672-217309CC-C411-4FD6-942B-058A7A28E1A4Q34438331-C14ABBD4-73F5-4E1B-A0D6-D49A2A3429FBQ34438608-92640425-A74A-4892-BD0D-4DD62AB9B59FQ34455259-0E522B89-D641-423B-8016-9BE2903833F6Q34518568-989E8987-9A85-45BF-956E-1D9B69A26B3AQ34662879-EC62D621-0095-400D-A36C-6E44C6B53772
P50
name
Aladar A Szalay
@en
type
label
Aladar A Szalay
@en
prefLabel
Aladar A Szalay
@en